IOSAT™ - (Potassium Iodide Tablets, USP, 130 mg)

Manufacturer
Anbex Inc.
Effective date
2025-10-03
Label type
HUMAN OTC DRUG LABEL
Version
12
Source
full-release
Hydrated at
2026-06-01 01:15:53

Label at a glance#

ProductIOSAT
Active ingredientPOTASSIUM IODIDE
Label structure18 sections

Indications and uses

Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.

Dosage and administration

use as directed by public officials in the event of a nuclear radiation emergency do not take more than 1 dose in 24 hours tablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrup The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture. Age D...

Storage and handling

Store at 20-25°C (68-77°F). Keep dry and foil intact.

Label contents#

Full prescribing information#

Active Ingredients (in each tablet )

OTC - ACTIVE INGREDIENT SECTION

Potassium iodide 130 mg

Purpose

OTC - PURPOSE SECTION

Thyroid blocking

Uses

INDICATIONS & USAGE SECTION

Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.

Warnings

WARNINGS SECTION

Allergy alert:Iodine may cause an allergic reaction with 1 or more of the following symptoms:

  • shortness of breath or wheezing
  • swelling
  • skin rash
  • trouble breathing, speaking or swallowing
  • fever and joint pain

Do not useif you have

OTC - DO NOT USE SECTION

  • ever had an allergic reaction to iodine
  • nodular thyroid disease with heart disease
  • hypocomplementemic vasculitis
  • dermatitis herpetiformis

Stop use and ask a doctor ifyou have

OTC - STOP USE SECTION

  • an allergic reaction. Get medical help right away if you have trouble breathing, speaking or swallowing; shortness of breath; wheezing; swelling of the mouth, tongue or throat; or rash.
  • irregular heartbeat or chest pain. Get medical help right away.
  • swelling of the hands or feet, fever, or joint pain.

Keep out of reach of children.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

  • use as directed by public officials in the event of a nuclear radiation emergency
  • do not take more than 1 dose in 24 hours
  • tablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrup

The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture.

AgeDose
Adults over 18 years1 tablet (whole or crushed) daily (130 mg)
Children over 12 years to 18 years who weigh at least 150 pounds1 tablet (whole or crushed) daily (130 mg)
Children over 12 years to 18 years who weigh less than 150 pounds1/2 tablet (whole or crushed) daily (65 mg)
Children over 3 years to 12 years1/2 tablet (whole or crushed) daily (65 mg)
Children over 1 month to 3 years32.5 mg daily as directed in the consumer package insert
Birth to 1 month16.25 mg daily as directed in the consumer package insert
  • If pregnant, breastfeeding, have a baby up to 1 month of age or have thyroid disease (except nodular thyroid disease with heart disease), take as directed above and contact a doctor as soon as possible.

Other Information

SPL UNCLASSIFIED SECTION

  • store at 20-25°C (68-77°F)
  • keep dry and foil intact
  • protect from light
  • do not throw away consumer package insert

Inactive ingredients

INACTIVE INGREDIENT SECTION

magnesium stearate, microcrystalline cellulose, silica gel, sodium thiosulfate

Questions or Comments?

OTC - QUESTIONS SECTION

call toll free 1-866-463-6754

Distributed by:

SPL UNCLASSIFIED SECTION

ANBEX INC.
1812 West Sunset Blvd, Suite 1A-618
St George, UT 84770
(833) 467-2854

www.anbex.com• www.iosat.com

Consumer Package Insert

SPL PATIENT PACKAGE INSERT SECTION

IOSAT™

(Potassium Iodide Tablets USP, 130 mg)
(Abbreviated KI)

Take potassium iodide (KI) only when public officials tell you. In a nuclear radiation emergency, radioactive iodine could be released into the air. KI protects only the thyroid gland from uptake of radioactive iodine. Therefore, KI should be used along with other emergency measures that will be recommended to you by public officials. If you are told to take this medicine, take it 1 time every 24 hours. Do not take it more often. More KI will not help you. Too much KI may increase the chances of side effects. Do not take this medicine if you know you are allergic to iodine (see SIDE EFFECTS below).

DESCRIPTION

DESCRIPTION SECTION

Each white, round, cross-scored—the name IOSAT stamped on one side—tablet contains 130 mg of potassium iodide.

INDICATIONS

INDICATIONS & USAGE SECTION

IOSAT™(Potassium Iodide tablets, USP, 130 mg) is a thyroid blocking medicine that is used in a nuclear radiation emergency only.

DIRECTIONS FOR USE

SPL UNCLASSIFIED SECTION

Use only as directed by public officials if a nuclear radiation emergency happens.

AgeDose
Adults over 18 years1 tablet (whole or crushed) every day (130 mg)
Children over 12 years to 18 years who weigh at least 150 pounds1 tablet (whole or crushed) every day (130 mg)
Children over 12 years to 18 years who weigh less than 150 pounds1/2 tablet (whole or crushed) every day (65 mg)
Children over 3 years to 12 years1/2 tablet (whole or crushed) or 4 teaspoonfuls every day (65 mg)
Children over 1 month to 3 years2 teaspoonfuls every day (32.5 mg)
Birth to 1 month1 teaspoonful every day (16.25 mg)

Tablets can be crushed and mixed in many liquids. To take the tablet in liquid solution, use dosing directions under Making a Potassium Iodide Liquid Mixture.

Take KI every day (every 24 hours) as directed by public officials. Do not take more than 1 dose in 24 hours. More will not help you. Too much medicine may increase the chances of side effects.

Making a Potassium Iodide Liquid Mixture:

  1. Put one130 mg KI tablet into a small bowl and grind it into a fine powder using the back of a metal teaspoon against the inside of the bowl. The powder should not have any large pieces.
  2. Add 4 teaspoonfuls of water to the crushed KI powder in the bowl and mix until the KI powder is dissolved in the water.
  3. Take the KI water mixture solution made in step 2 and mix it with 4 teaspoonfuls of low fat white or chocolate milk, orange juice, flat soda, raspberry syrup, or infant formula.
  4. The KI liquid mixture will keep for up to 7 days in the refrigerator. It is recommended that the KI liquid mixture be prepared weekly. Throw away unused portions.

The amount of KI (130 mg tablet) in the drink when mixed as described above is 16.25 mg per teaspoonful. The number of teaspoonfuls of the drink to give your child depends on your child’s age as described in the following table:

Child's AgeGive your child this amount in teaspoonfuls
Over 12 years to 18 years who weigh less than 150 pounds4 teaspoonfuls will give you a 65 mg dose
Over 3 years to 12 years old4 teaspoonfuls will give you a 65 mg dose
Over 1 month to 3 years old2 teaspoonfuls will give you a 32.5 mg dose
Birth to 1 month1 teaspoonful will give you a 16.25 mg dose

Note: This is the amount to give your child for onesingle dose in teaspoonfuls(not tablespoonfuls). You should give your child one dose each day as recommended by the public officials.

Pregnant or breastfeeding women, or babies under 1 month of age:Take as directed above and call a doctor as soon as possible. Repeat dosing should be avoided. It is recommended that thyroid function be checked in babies less than 1 month of age that take KI. Women who are pregnant or breastfeeding should also be checked by a doctor if repeat dosing is necessary. Although these precautions should be taken, the benefits of short-term use of KI to block uptake of radioactive iodine by the thyroid gland far exceed its chances of side effects.

Patients with thyroid disease:If you have both a nodular thyroid condition such as multinodular goiter with heart disease, you should not take KI. Patients with other thyroid conditions may take KI as directed above, but call a doctor if you need to take KI for more than a few days.

WARNING

WARNINGS SECTION

People who are allergic to iodine, have dermatitis herpetiformis or hypocomplementemic vasculitis, or have nodular thyroid disease with heart disease should not take KI. Keep out of the reach of children. In case of an allergic reaction (difficulty breathing, speaking or swallowing; wheezing; shortness of breath or swelling of the mouth or throat), call 911 or get medical care right away. In case of overdose, get medical help or call a Poison Control Center right away.

HOW POTASSIUM IODIDE WORKS

SPL UNCLASSIFIED SECTION

Certain forms of iodine help your thyroid gland work right. Most people get the iodine they need from foods like iodized salt or fish. The thyroid can “store” or hold only a certain amount of iodine.

In nuclear radiation emergency, radioactive iodine may be released in the air. This material may be breathed or swallowed. It may enter the thyroid gland and damage it. The damage would probably not show itself for years. Children are most likely to have thyroid damage.

If you take KI, it will block or reduce the chances that radioactive iodine will enter your thyroid gland.

WHO SHOULD NOT TAKE POTASSIUM IODIDE

SPL UNCLASSIFIED SECTION

People should avoid KI if they are allergic to iodine, have dermatitis herpetiformis or hypocomplementemic vasculitis, or have nodular thyroid disease with heart disease, because these conditions may increase the chances of side effects to iodine.

HOW AND WHEN TO TAKE POTASSIUM IODIDE

SPL UNCLASSIFIED SECTION

KI should be taken as soon as possible after public officials tell you. If you are told to repeat the dose, you should take the second dose 24 hours after the first dose. Do not take it sooner. More KI will not help you because the thyroid can “hold” only certain amounts of iodine. Taking more than 1 dose per day will increase the chances of side effects. The public officials will tell you how many days to take KI. You should take KI until the chances of major exposure to radioactive iodine by breathing or swallowing stops.

SIDE EFFECTS

SPL UNCLASSIFIED SECTION

Short-term use of KI at the recommended dose is safe. You should not take this drug for longer than you are told.

Possible side effects include: swelling of the salivary glands, nausea, vomiting, diarrhea, stomach ache, fever, headache, metallic taste, and allergic reactions. Allergic reaction can include

  • skin rashes such as hives
  • swelling of various parts of the body such as the face, lips, tongue, throat, hands or feet
  • fever with joint pain
  • trouble breathing, speaking or swallowing
  • wheezing or shortness of breath

Get medical attention right away if you have trouble breathing, speaking or swallowing; wheezing; shortness of breath; or swelling of the mouth, tongue or throat.

Taking iodide, in rare cases, may cause overactivity of the thyroid gland, underactivity of the thyroid gland, or enlargement of the thyroid gland (goiter). Symptoms of an overactive thyroid gland may include an irregular heartbeat and chest pain. Patients with thyroid disease are more likely to get these side effects. Babies under 1 month of age are more likely to get an underactive thyroid gland (hypothyroidism).

WHAT TO DO IF SIDE EFFECTS OCCUR

SPL UNCLASSIFIED SECTION

Stop taking KI and call a doctor if you have one of the following symptoms:

SPL UNCLASSIFIED SECTION

  • swelling of the face, hands or feet
  • fever and joint pain
  • skin rash
Stop taking KI and get medical help right away if you have one or more of the following symptoms:

SPL UNCLASSIFIED SECTION

  • trouble breathing, speaking or swallowing
  • shortness of breath or wheezing
  • swelling of the lips, tongue or throat
  • irregular heart beat or chest pain

HOW SUPPLIED

HOW SUPPLIED SECTION

IOSAT™(Potassium Iodide Tablets, USP 130 mg) Each white, round tablet, cross-scored on one side and the IOSAT name on the other, contains 130 mg potassium iodide.
NDC 51803-001-01: 14 Unit dose, Foil Sealed, 130 mg Tablets.
NDC 51803-001-10: 10 X 14 Unit dose, Foiled Sealed 130 mg tablets (140 tablets) in a Clear Plastic Bag.

Also available:IOSAT™(Potassium Iodide Tablets, USP 65 mg) Packages of 20 tablets. Each white, round tablet, cross-scored on one side and the IOSAT name on the other, contains 65 mg potassium iodide.
NDC 51803-002-01: 2 X 10 Unit dose, Foil Sealed, 65 mg Tablets (20 Tablets).

STORAGE AND HANDLING

STORAGE AND HANDLING SECTION

Store at 20-25°C (68-77°F). Keep dry and foil intact.

Distributed by:

SPL UNCLASSIFIED SECTION

ANBEX INC.
1812 West Sunset Blvd, Suite 1A-618
St George, UT 84770
(833) 467-2854
www.anbex.com
www.iosat.com

SH905-1
8/23

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

IOSAT™ (Potassium Iodide Tablets, USP 130 mg)

iosat 130 package labeliosat 130 package label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1111703Iosat 130 MG Oral TabletPSN12
312539potassium iodide 130 MG Oral TabletPSN12
1111703potassium iodide 130 MG Oral Tablet [Iosat]SBD12
312539potassium iodide 130 MG Oral TabletSCD12
1111703Iosat 130 MG Oral TabletSY12
312539K+ Iodide 130 MG Oral TabletSY12
1111703K+ Iodide 130 MG Oral Tablet [Iosat]SY12
312539Pot Iodide 130 MG Oral TabletSY12
1111703Pot Iodide 130 MG Oral Tablet [Iosat]SY12

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
51803-001-01IOSAT14 in 1 PACKAGETABLET1412
51803-001-10IOSAT10 in 1 BAGTABLET1012

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51803-001-01EA - Each51803-0016a5ba3f9-288b-4d2f-a7eb-b1ccadabcf5212017-03-06
51803-001-10EA - Each51803-001f65923a6-f4ec-4d13-b221-8a00531581ba12020-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
POTASSIUM IODIDEACTIVE INGREDIENT1C4QK22F9J2
IODIDE IONACTIVE MOIETY09G4I6V86Q2
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61U2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU42
SODIUM THIOSULFATE ANHYDROUSINACTIVE INGREDIENTL0IYT1O31N2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51803-00151803-001-01, 51803-001-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 12 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM THIOSULFATE ANHYDROUSSODIUM THIOSULFATE ANHYDROUSL0IYT1O31NTABLET / ORAL0.06 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SODIUM THIOSULFATE ANHYDROUSSODIUM THIOSULFATE ANHYDROUSL0IYT1O31NTABLET / ORAL0.06 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET / ORAL750 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / ORAL6184 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SODIUM THIOSULFATE ANHYDROUSSODIUM THIOSULFATE ANHYDROUSL0IYT1O31NTABLET / ORAL0.06 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET / ORAL750 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / ORAL6184 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET / ORAL750 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / ORAL6184 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018664-001IOSATPOTASSIUM IODIDE130MGTABLET / ORALRLD, RS1982-10-14
N018664-002IOSATPOTASSIUM IODIDE65MGTABLET / ORALRLD2011-05-12

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-1484e616aacf4f…
2026-09-14 22:38:342026-08N018664-002IOSAT65MGTABLET / ORALRLD2011-05-1284e616aacf4f…
2026-08-18 06:07:402026-07N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14caaa826d4ba7…
2026-08-18 06:07:402026-07N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-1431067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018664-002IOSAT65MGTABLET / ORALRLD2011-05-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-146a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018664-002IOSAT65MGTABLET / ORALRLD2011-05-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-1403ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018664-002IOSAT65MGTABLET / ORALRLD2011-05-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-142680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018664-002IOSAT65MGTABLET / ORALRLD2011-05-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-145bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018664-002IOSAT65MGTABLET / ORALRLD2011-05-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14d06236e962d9…
2024-10-29 15:01 UTC2024-10N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-1479d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018664-002IOSAT65MGTABLET / ORALRLD2011-05-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-14301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018664-002IOSAT65MGTABLET / ORALRLD2011-05-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-141e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018664-002IOSAT65MGTABLET / ORALRLD2011-05-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-148072bd15b7f6…
2024-05-31 18:47 UTC2024-05N018664-002IOSAT65MGTABLET / ORALRLD2011-05-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-145c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018664-002IOSAT65MGTABLET / ORALRLD2011-05-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-145d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N018664-002IOSAT65MGTABLET / ORALRLD2011-05-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-144b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N018664-002IOSAT65MGTABLET / ORALRLD2011-05-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018664-001IOSAT130MGTABLET / ORALRLD, RS1982-10-1474a2ff9319b5…
2019-12-13 00:20 UTC2019-12N018664-002IOSAT65MGTABLET / ORALRLD2011-05-1274a2ff9319b5…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
IOSATPOTASSIUM IODIDEAnbex Inc.ea98aef8-93b6-4fac-be35-eb17a1a04a922025-10-03WarningsExact identifier
ndc (package): 51803-001-01
ndc (package): 51803-001-10
ndc (product): 51803-001
ndc11 (package): 51803000110
ndc11 (package): 51803000101
spl id: 40435397-14e1-e00c-e063-6294a90a3262
spl set id: ea98aef8-93b6-4fac-be35-eb17a1a04a92

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.